Eijkman Institute for Molecular Biology, Jakarta, Indonesia   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Jakarta Indonesia (1888)

Organization Overview

First Clinical Trial
2014
NCT02001428
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Eijkman Institute for Molecular Biology | Eijkman Institute, Jakarta, Indonesia | Eijkman Oxford Clinical Research Unit, Eijkman Institute | Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Indonesia | Eijkman Oxford Clinical Research Unit, Indonesia

Active Ingredients

Drugs in Phase 3 Trials (2)

COVID-19 convalescent plasma (2 trials)

urea (1 trial)

Drugs in Phase 2 Trials (3)

chloroquine (1 trial)

metformin (glucophage) (1 trial)

pfspz (1 trial)

Drugs in Other Trials (2)

dihydroartemisinin (1 trial)

piperaquine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chemical and Drug Induced Liver Injury (Phase 3)

Convalescence (Phase 1)

Coronavirus Infections (Phase 1)

Malaria (Phase 2)

Meningitis (Phase 3)

Severe Acute Respiratory Syndrome (Phase 1)

Tuberculosis (Phase 3)

Tuberculosis, Meningeal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 7